BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9032100)

  • 1. Insulin lispro in CSII: results of a double-blind crossover study.
    Zinman B; Tildesley H; Chiasson JL; Tsui E; Strack T
    Diabetes; 1997 Mar; 46(3):440-3. PubMed ID: 9032100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin.
    Tsui EY; Chiasson JL; Tildesley H; Barnie A; Simkins S; Strack T; Zinman B
    Diabetes Care; 1998 Jan; 21(1):93-6. PubMed ID: 9538976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study.
    Johansson UB; Adamson UC; Lins PE; Wredling RA
    Diabetes Metab; 2000 May; 26(3):192-6. PubMed ID: 10880892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.
    Annuzzi G; Del Prato S; Arcari R; Bellomo Damato A; Benzi L; Bruttomesso D; Calderini MC; Coscelli C; Fedele D; Galluzzo A; Giordano M; Giorgino R; Lapolla A; Orsini P; Pagano G; Santoro D; Riccardi G
    Nutr Metab Cardiovasc Dis; 2001 Jun; 11(3):168-75. PubMed ID: 11590992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps.
    Melki V; Renard E; Lassmann-Vague V; Boivin S; Guerci B; Hanaire-Broutin H; Bringer J; Belicar P; Jeandidier N; Meyer L; Blin P; Augendre-Ferrante B; Tauber JP
    Diabetes Care; 1998 Jun; 21(6):977-82. PubMed ID: 9614617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.
    Launay B; Zinman B; Tildesley HD; Strack T; Chiasson JL
    Diabetes Care; 1998 Oct; 21(10):1627-31. PubMed ID: 9773721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents.
    Holcombe JH; Zalani S; Arora VK; Mast CJ;
    Clin Ther; 2002 Apr; 24(4):629-38. PubMed ID: 12017407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H; Melki V; Bessières-Lacombe S; Tauber JP
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes.
    Deeb LC; Holcombe JH; Brunelle R; Zalani S; Brink S; Jenner M; Kitson H; Perlman K; Spencer M
    Pediatrics; 2001 Nov; 108(5):1175-9. PubMed ID: 11694699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group.
    Zinman B; Ross S; Campos RV; Strack T
    Diabetes Care; 1999 Apr; 22(4):603-8. PubMed ID: 10189539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
    Reichel A; Rietzsch H; Köhler HJ; Pfützner A; Gudat U; Schulze J
    Exp Clin Endocrinol Diabetes; 1998; 106(3):168-72. PubMed ID: 9710355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group.
    Holleman F; Schmitt H; Rottiers R; Rees A; Symanowski S; Anderson JH
    Diabetes Care; 1997 Dec; 20(12):1827-32. PubMed ID: 9405901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
    Vignati L; Anderson JH; Iversen PW
    Clin Ther; 1997; 19(6):1408-21. PubMed ID: 9444449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.
    Ciofetta M; Lalli C; Del Sindaco P; Torlone E; Pampanelli S; Mauro L; Chiara DL; Brunetti P; Bolli GB
    Diabetes Care; 1999 May; 22(5):795-800. PubMed ID: 10332684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.